We are live on ! Find out more
OIM

Oracle Investment Management Portfolio holdings

AUM $168M
1-Year Est. Return 42.86%
This Fund
S&P 500
This Quarter Est. Return
+57.27%
1 Year Est. Return
+42.86%
3 Year Est. Return
+864.89%
5 Year Est. Return
+1,153.35%
10 Year Est. Return
+22,228.86%
AUM
$470M
AUM Growth
+$148M
Cap. Flow
+$20.9M
Cap. Flow %
4.45%
Top 10 Hldgs %
95.78%
Holding
21
New
2
Increased
5
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$36.6M
2
DERM
Dermira, Inc.
DERM
+$11.4M
3
AXDX
Accelerate Diagnostics
AXDX
+$2.84M
4
AMRN
Amarin Corp
AMRN
+$451K
5
SLNO
Soleno Therapeutics
SLNO
+$231K

Top Sells

Rank Stock Value
1
TSRO
TESARO, Inc.
TSRO
+$35M
2
PACB icon
Pacific Biosciences
PACB
+$10.5M
3
ADAP
Adaptimmune Therapeutics
ADAP
+$304K
4
CFRX
ContraFect Corporation
CFRX
+$53.7K

Sector Composition

Rank Sector Weight
1 Healthcare 95.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QDEL icon
1
QuidelOrtho
QDEL
$1.21B
$125M 26.52%
1,903,558
– –
AMRN
2
Amarin Corp
AMRN
$297M
$109M 23.09%
261,329
+1,250
+0.5% +$451K
AXDX
3
DELISTED
Accelerate Diagnostics
AXDX
$91.4M 19.45%
434,956
+15,154
+4% +$2.84M
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$52.6M 11.19%
1,021,392
+846,857
+485% +$36.6M
DERM
5
DELISTED
Dermira, Inc.
DERM
$18.5M 3.94%
+1,367,436
New +$11.4M
BIOL
6
DELISTED
Biolase, Inc.
BIOL
$14.7M 3.13%
2,469
– –
VRML
7
DELISTED
Vermillion, Inc.
VRML
$11.3M 2.4%
9,825,289
– –
MOTS
8
DELISTED
Motus GI Holdings, Inc. Common Stock
MOTS
$10.8M 2.3%
9,250
– –
OPK icon
9
Opko Health
OPK
$978M
$9.62M 2.05%
3,686,194
– –
PACB icon
10
Pacific Biosciences
PACB
$441M
$8.03M 1.71%
1,110,666
-1,447,098
-57% -$10.5M
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
$7.86M 1.67%
254,237
+8,691
+4% +$231K
AGEN
12
Agenus
AGEN
$326M
$4.04M 0.86%
69,237
– –
BHVN
13
CALL
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$3.42M 0.73%
+739,000
New +$31.9M
CFRX
14
DELISTED
ContraFect Corporation
CFRX
$2.24M 0.48%
7,026
-124
-2% -$53.7K
BIIB icon
15
Biogen
BIIB
$29.8B
$1.5M 0.32%
6,368
– –
AMRN
16
CALL
Amarin Corp
AMRN
$297M
$410K 0.09%
8,270
+3,270
+65% +$1.18M
AXDX
17
CALL
DELISTED
Accelerate Diagnostics
AXDX
$377K 0.08%
20,640
-40,710
-66% -$7.63M
PACB icon
18
CALL
Pacific Biosciences
PACB
$441M
$13K ﹤0.01%
500,000
-1,409,600
-74% -$10.2M
ADAP
19
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-52,921
Closed -$304K
QDEL icon
20
CALL
QuidelOrtho
QDEL
$1.21B
– –
-144,100
Closed -$52K
TSRO
21
DELISTED
TESARO, Inc.
TSRO
– –
-471,500
Closed -$35M

Similar funds

BIO
Blue Investment Opportunities Miami Beach, Florida $168M AUM 21.32% 1-Year Est. Return
OBWA
Oak Barrel Wealth Advisory Reston, Virginia $167M AUM
EECFX
EnCap Energy Capital Fund XII Houston, Texas $169M AUM
PW
Pandora Wealth Oakbrook Terrace, Illinois $165M AUM 18.5% 1-Year Est. Return
PWA
Principia Wealth Advisory Dallas, Texas $160M AUM 37.01% 1-Year Est. Return
AIMU
Allianz Investment Management US Minneapolis, Minnesota $160M AUM 4.75% 1-Year Est. Return
HIA
Harvest Investment Advisors Tallahassee, Florida $176M AUM
ACA
AG Campbell Advisory Baltimore, Maryland $158M AUM

Oracle Investment Management's Q1 2019 Portfolio in Review

As of Q1 2019, Oracle Investment Management held 21 positions worth $470M, up 46% from $322M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Oracle Investment Management deployed $20.9M of net new capital in Q1 2019, opening 2 new positions and adding to 5 existing holdings. Its largest new stake was Dermira, Inc.: 1,367,436 shares worth $18.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was Pacific Biosciences, an estimated $10.5M trimmed.

  • Oracle Investment Management's largest Q1 2019 buy was Dermira, Inc.: 1,367,436 shares worth $18.5M.
  • Oracle Investment Management added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019, an estimated $36.6M increase.
  • Oracle Investment Management's biggest Q1 2019 reduction was Pacific Biosciences, cutting an estimated $10.5M.
  • Oracle Investment Management fully exited TESARO, Inc. in Q1 2019, selling an estimated $35M.
  • Oracle Investment Management's ten largest holdings make up 96% of its $470M portfolio in Q1 2019.
  • Oracle Investment Management opened 2 new positions and closed 3 in Q1 2019.
  • Oracle Investment Management's portfolio value rose 46% quarter-over-quarter to $470M.

Based on Oracle Investment Management's 13F filing for Q1 2019, filed 15 May 2019.